Safety and effectiveness of oral hypoglycemic agents in women with gestational diabetes. Literature Review

Background: The aim of this article is to review the estimates of studies have proposed the use of oral hypoglycemic agents (HGO) for metabolic control in patients with Gestational Diabetes Mellitus (GDM), evaluating outcomes regarding effectiveness and safety: breast, fetal, obstetric and neonatal...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2014
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/24156
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/24156
Palabra clave:
Oral antidiabetic agent
Article
Clinical trial (topic)
Cost benefit analysis
Drug efficacy
Drug safety
Human
Insulin treatment
Meta analysis (topic)
Pregnancy diabetes mellitus
Pregnancy outcome
Systematic review (topic)
Treatment outcome
Female
Humans
Hypoglycemic agents
Pregnancy
Gestational diabetes
Glyburide
Insulin
Metformin
Oral hypoglycemic agents
oral
gestational
Administration
Diabetes
Rights
License
Abierto (Texto Completo)
Description
Summary:Background: The aim of this article is to review the estimates of studies have proposed the use of oral hypoglycemic agents (HGO) for metabolic control in patients with Gestational Diabetes Mellitus (GDM), evaluating outcomes regarding effectiveness and safety: breast, fetal, obstetric and neonatal outcome; comparing these outcomes with insulin therapy and among themselves, in order to contribute to understand the risks and benefits of using HGO in the current management of GDM. Materials and methods: A review was carried out in the literature recorded in four databases: PubMed, Ovid, Cochrane and ProQuest, between December 2007 and December 2012. Results: Clinical trials (n = 7), meta-analysis (n = 2), systematic reviews (n = 2), cohort studies: (n = 3), cost analysis study (n = 1) and ranked 15 items were included. Conclusion: HGO provide adequate control of maternal glycemia and perinatal results comparable insulin therapy, and they should be considered as effective and safe option in the treatment of GDM.